StewartJ.F., RubensR.D., KingR.J.B.: Contribution of prednisolone to the primary endocrine therapy of advanced breast cancer. Eur J Cancer Clin Oncol18: 1307–1314, 1982.
2.
CastiglioneM., GelberR.D., GoldhirschA.: Adjuvant systemic therapy for breast cancer in the elderly: competing causes of mortality. J Clin Oncol, 8: 519–526, 1990.
3.
GelmanR.S., TaylorS.G.: Cyclophosphamide, methotrexate, and fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol, 2: 1404–1413, 1984.
4.
BonadonnaG., ValagussaP., RossiA.: Ten-year experience with CMF based adjuvant chemotherapy in resectable breast cancer. Breast Cancer Res Treat, 5: 95–115, 1985.
5.
The International Breast Cancer Study Group:Effectiveness of adjuvant chemotherapy in combination with tamoxifen for node-positive postmenopausal breast cancer patients. J Clin Oncol15: 1385–1394, 1997.
6.
CrivellariD., BonettiM., Castiglione-GertschM.: Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: The International Breast Cancer Study Group Trial VII. J Clin Oncol, 18: 1412–1422, 2000.
7.
Early Breast Cancer Trialists’ Collaborative Group:Polychemotherapy for early breast cancer: An overview of the randomized trials. Lancet, 352: 930–942, 1998.
8.
McDonaldC.C., AlexanderFE, WhyteB.W.: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomised trial. BMJ, 311: 977–980, 1995
